Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial

Trial ID: NCT04998552

Interventional - Phase Unknown - Recruiting

The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.

Conditions

Interventions

Eligibility

Inclusion criteria

Exclusion criteria

Sponsor

Capital Health System, Inc

Source: Clinicaltrials.gov

Search more clinical trials on myTomorrows